SPRINGFIELD, Mo.--(BUSINESS WIRE)--QPS’ clinical research unit, Bio-Kinetic Clinical Applications, announces a joint collaboration with Quintiles that creates an integrated Cardiac Safety Service for sponsors by incorporating clinical conduct, core ECG laboratory support, independent cardiologist and medical monitor oversight, pharmacokinetic and statistical analysis, and reporting of cardiac safety trials. These clinical trials, commonly called Thorough QTc (TQT) studies, typically are done early in development and evaluate a drug’s effect on cardiac repolarization by indentifying any QT/QTc interval prolongation and/or proarrhythmic potential using methods described in ICH E14. This formal collaboration between QPS’ Bio-Kinetic Phase I unit and Quintiles is the culmination of more than a 10-year relationship of conducting many Phase I clinical trials together, including TQT studies.
